WO2004002399A2 - Use of gaba-c receptor antagonists for the treatment of myopia - Google Patents
Use of gaba-c receptor antagonists for the treatment of myopia Download PDFInfo
- Publication number
- WO2004002399A2 WO2004002399A2 PCT/EP2003/006850 EP0306850W WO2004002399A2 WO 2004002399 A2 WO2004002399 A2 WO 2004002399A2 EP 0306850 W EP0306850 W EP 0306850W WO 2004002399 A2 WO2004002399 A2 WO 2004002399A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gaba
- antagonist
- halogen
- myopia
- optionally substituted
- Prior art date
Links
- SESMXKBCYKQVNL-UHFFFAOYSA-N CCP(C1=CCNCC1)(OC)=O Chemical compound CCP(C1=CCNCC1)(OC)=O SESMXKBCYKQVNL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Definitions
- WO 98/58939 describes TPMPA as a selective GABA-C antagonist, which shall exhibit cognitive enhancing activity.
- a GABA-C receptor antagonist such as TPMPA, has a useful efficacy in the treatment of myopia.
- the present invention provides a method of treating myopia in an individual in need of such treatment, comprising the step of administering an effective amount of a GABA-C receptor antagonist to said individual.
- the invention also pertains to the use of a GABA-C receptor antagonist in the manufacture of a medicament for the treatment of myopia.
- a GABA-C receptor antagonist should preferably be substantially inactive with respect to any efficacy for the receptor selected from GABA-B.
- a GABA-C receptor antagonist should preferably be substantially inactive with respect to any efficacy for the receptors selected from GABA-A and GABA-B.
- substantially inactive refers to an IC 50 value being typically above 50 micromolar, preferably above 100 micromolar, more preferably above 250 micromolar and in particular above 500 micromolar.
- a selective GABA-C receptor antagonist has typically an ICso-value being less than 40 micromolar, preferably less than 10 micromolar, more preferably less than 1 micromolar, and in particular in the range of 1 - 0.0001 micromolar, and more particular from 0.1 - 0.001 micromolar.
- GABA-C antagonists suitable to treat myopia are for example represented by general formula I or general formula II,
- X represents hydrogen, an alkyl group optionally substituted with a halogen, or a hydroxyalkyl group
- Alkyl has up to 20 carbon atoms and may be straight-chained or branched. Alkyl is preferably lower alkyl having up to 8 carbon atoms, especially up to 4, and more especially up to 2, carbon atoms. Suitable examples include dodecyl, octyl, hexyl, pentyl, butyl, propyl, ethyl, methyl, 2-propyl, 2-butyl and 3-pentyl.
- Alkenyl has from 2 to 20 carbon atoms and may be linear or branched. Alkenyl is especially lower alkenyl having from 2 to 8 carbon atoms, preferably from 2 to 6 carbon atoms and especially from 2 to 4 carbon atoms. Examples of alkenyl are vinyl, allyl, 1-propen-2-yl, 1- buten-2- or -3- or -4-yl, 2-buten-3-yl, and the isomers of pentenyl, hexenyl and octenyl.
- Alkynyl has from 2 to 20 carbon atoms and may be linear or branched. Alkynyl is especially lower alkynyl having from 2 to 8 carbon atoms, preferably from 2 to 6 carbon atoms and especially from 2 to 4 carbon atoms. Examples of alkynyl are ethynyl, propargyl, 1-butyn-1-, 3- or -4-yl, and the isomers of pentynyl, hexynyl and octynyl.
- Halogen is especially fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine and more especially fluorine or chlorine.
- Alkoxy has up to 20 carbon atoms and is preferably lower alkoxy.
- Lower alkoxy has up to 8 carbon atoms, preferably up to 6 carbon atoms, and is, for example, methoxy, ethoxy, propoxy, butoxy, tert-butoxy or hexyloxy.
- Acyl has up to 20 carbon atoms and may be straight-chain or branched, preferably lower acyl having up to 8 carbon atoms, especially up to 4, and more especially up to 2, carbon atoms, and is for example acetyl.
- the invention provides the use of a compound having GABA- C antagonist activity, being in particular selected from the group of formula I and formula II as defined above, in the manufacture of a medicament for the treatment of myopia.
- a method for the treatment of myopia comprising the administration of a compound selected from the group of formula I and formula II as defined above to a patient in need of such treatment.
- GABA-C antagonists examples include GABA-C antagonists and their receptor profile.
- the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage may be in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound. An administration may conveniently be administered in divided doses up to 4 times a day or in sustained release form.
- the compounds used in the invention may be administered in free form or in pharmaceutically acceptable salt form, provided said compound is able to form a salt.
- Such salts may be prepared in conventional manner and exhibit typically the same order of activity as the free compounds.
- Compounds according to the invention may be administered by any conventional route, for example intravitreally, e.g. in form of injectable solutions or suspensions, enterally, preferably orally, e.g. in the form of tablets or capsules, topically, e.g. ophthalmically, e.g. in the form of eye drops, gels, or ointments.
- intravitreally e.g. in form of injectable solutions or suspensions
- enterally preferably orally, e.g. in the form of tablets or capsules
- topically e.g. ophthalmically, e.g. in the form of eye drops, gels, or ointments.
- the invention relates to an ophthalmic composition
- a ophthalmic composition comprising an effective amount of a GABA-C antagonist and a carrier, which composition is suitable for topical ocular administration.
- Preferred carriers are water, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulos ⁇ , hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose and hydroxypropylcellulose, neutral Carbopol, or mixtures thereof.
- a highly preferred carrier is water.
- the concentration of the carrier is, for example, from 1 to 100000 times the concentration of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003245995A AU2003245995A1 (en) | 2002-06-28 | 2003-06-27 | Use of gaba-c receptor antagonists for the treatment of myopia |
JP2004516732A JP2005533082A (en) | 2002-06-28 | 2003-06-27 | Use of GABA-C receptor antagonists for the treatment of myopia |
US10/516,246 US20060142249A1 (en) | 2002-06-28 | 2003-06-27 | Ophthalmic use |
EP03738095A EP1526858A2 (en) | 2002-06-28 | 2003-06-27 | Use of gaba-c receptor antagonists for the treatment of myopia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02014412 | 2002-06-28 | ||
EP02014412.7 | 2002-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004002399A2 true WO2004002399A2 (en) | 2004-01-08 |
WO2004002399A3 WO2004002399A3 (en) | 2004-04-01 |
Family
ID=29797147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/006850 WO2004002399A2 (en) | 2002-06-28 | 2003-06-27 | Use of gaba-c receptor antagonists for the treatment of myopia |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060142249A1 (en) |
EP (1) | EP1526858A2 (en) |
JP (1) | JP2005533082A (en) |
AU (1) | AU2003245995A1 (en) |
WO (1) | WO2004002399A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11890266B2 (en) | 2016-04-11 | 2024-02-06 | University Of Canberra | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
US5627169A (en) * | 1994-07-20 | 1997-05-06 | The Regents Of The University Of California | Selective antagonists for GABArho receptor |
WO1998028313A1 (en) * | 1996-12-24 | 1998-07-02 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
WO1998058939A1 (en) * | 1997-06-23 | 1998-12-30 | Polychip Pharmaceuticals Pty. Ltd. | Neurologically-active compounds |
WO2003032975A1 (en) * | 2001-10-16 | 2003-04-24 | The Trustees Of The University Of Pennsylvania | Modulation of ocular growth and myopia by gaba drugs |
-
2003
- 2003-06-27 JP JP2004516732A patent/JP2005533082A/en active Pending
- 2003-06-27 EP EP03738095A patent/EP1526858A2/en not_active Withdrawn
- 2003-06-27 WO PCT/EP2003/006850 patent/WO2004002399A2/en active Application Filing
- 2003-06-27 US US10/516,246 patent/US20060142249A1/en not_active Abandoned
- 2003-06-27 AU AU2003245995A patent/AU2003245995A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
US5627169A (en) * | 1994-07-20 | 1997-05-06 | The Regents Of The University Of California | Selective antagonists for GABArho receptor |
WO1998028313A1 (en) * | 1996-12-24 | 1998-07-02 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
WO1998058939A1 (en) * | 1997-06-23 | 1998-12-30 | Polychip Pharmaceuticals Pty. Ltd. | Neurologically-active compounds |
WO2003032975A1 (en) * | 2001-10-16 | 2003-04-24 | The Trustees Of The University Of Pennsylvania | Modulation of ocular growth and myopia by gaba drugs |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11890266B2 (en) | 2016-04-11 | 2024-02-06 | University Of Canberra | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier |
Also Published As
Publication number | Publication date |
---|---|
JP2005533082A (en) | 2005-11-04 |
WO2004002399A3 (en) | 2004-04-01 |
AU2003245995A1 (en) | 2004-01-19 |
AU2003245995A8 (en) | 2004-01-19 |
EP1526858A2 (en) | 2005-05-04 |
US20060142249A1 (en) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1094815B1 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
DE69423782T2 (en) | USE OF NON-STEROIDAL CYCLOOXYGENASE INHIBITORS FOR PRODUCING A MEDICINE FOR TREATING THE INCREASED EYE PRESSURE | |
CA2549801A1 (en) | Use of treprostinil to improve kidney functions | |
JP6466504B2 (en) | Alpha-2 adrenergic agonist with long-term intraocular pressure reduction effect | |
US20100004203A1 (en) | Medicament for preventive and/or therapeutic treatment of bowel disease | |
JP5542059B2 (en) | Antiallergic agent containing RXR agonist as active ingredient | |
NZ544417A (en) | Management of dementia and neurogenerative diseases with intermediate doses of LHRH antagonists | |
JPH1129483A (en) | Composition containing difluprednate | |
CA2660939A1 (en) | Pharmaceutical compositions for the treatment of fungal infections | |
NO313935B1 (en) | Use of angiotensin II antagonists for the preparation of a drug for the treatment of impaired nerve conduction velocity, especially diabetic neuropathy | |
JP6509244B2 (en) | Curing agent for crystalline lens | |
EP1526858A2 (en) | Use of gaba-c receptor antagonists for the treatment of myopia | |
US20120214763A1 (en) | Memory fixation accelerator | |
CA2443235A1 (en) | Pharmaceutical compositions comprising ascomycin | |
JPH0532635A (en) | Application of histamine derivative to therapy, a new histamine derivative and use of this derivative as medicine | |
CA2468811A1 (en) | Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders | |
JPH10109934A (en) | Agent for inflammatory eye disease | |
EP3487501A1 (en) | Methods, compositions, and compounds for treatment of dermatological and ocular conditions | |
JP2003201250A (en) | Pruritus-treating agent | |
MX2011003780A (en) | Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists. | |
JPH05262747A (en) | Therapeutic agent for ulcerative colitis | |
FR2731618A1 (en) | TOPICAL OPHTHALMIC COMPOSITION COMPRISING A 2- (4- (AZOLYLBUTYL) -PIPERAZINYL-METHYL) -BENZIMIDAZOLE DERIVATIVE, IN PARTICULAR FOR THE TREATMENT OF ALLERGIC CONJUNCTIVITIS | |
JP2002255812A (en) | Antipruritic agent | |
EP1663230A1 (en) | Compositions comprising benzo(g)quinoline derivatives and prostaglandin derivatives | |
Zhang et al. | [PP. 02.03] EFFICACY AND TOLERABILITY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYTEM 60MG IN CHINESE PATIENTS WITH UNCONTROLLED HYPERTENSION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PH PL PT RO RU SC SE SG SK TJ TM TN TR TT UA US UZ VC VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003738095 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004516732 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003738095 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006142249 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10516246 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10516246 Country of ref document: US |